Abstract
BackgroundThe pathogenesis of chronic spontaneous urticaria (CSU) and the mechanism of action of omalizumab in CSU remain unclear.ObjectiveIn this study, we assessed the responsiveness and FcεRI expression of various subsets of leucocytes in patients with CSU treated with omalizumab.MethodsIn this prospective cohort study, 30 patients were treated with 6 administrations of 300 mg omalizumab every 4 weeks, followed by a follow‐up period of 12 weeks. FcεRI expression and the percentage of basophils, monocytes, and dendritic cell subsets were analysed before and during treatment, and after follow‐up. In addition, anti‐IgE– and C5a‐induced basophil degranulation was measured. The results were correlated with disease activity and response to omalizumab.ResultsIn addition to a rapid and significant reduction in FcεRI on basophils, we demonstrated a reduction in FcεRI on plasmacytoid dendritic cells during omalizumab treatment, which persisted until 3 months after discontinuation. FcεRI expression on basophils and its reduction did not correlate with the treatment response. Omalizumab led to an increased percentage of basophils in blood but not of the other FcεRI‐bearing leucocytes. Basophil responsiveness was differentially affected; anti‐IgE–, but not C5a‐induced basophil degranulation increased during the treatment. Apart from clinical non‐responders showing a stronger increase in anti‐IgE–induced basophil degranulation over a period time, no differences were found in omalizumab responders vs non‐responders.Conclusions/Clinical RelevanceFcεRI expression on basophils decreased rapidly, while anti‐IgE–induced degranulation significantly increased due to omalizumab treatment in patients with CSU, persisting at least for 3 months after stopping the treatment. None of the markers were able to predict the effectiveness of treatment. Whether basophils play a role in omalizumab responsiveness in CSU remains unclear.
Highlights
Chronic spontaneous urticaria (CSU) manifests as a skin disease with a sudden onset of weals, which last longer than 6 weeks
Given the potential role of FcεRI-bearing leucocytes, in particular basophils, in the pathogenesis and/or treatment response to omalizumab, we evaluated the role of FcεRIbearing cells in chronic spontaneous urticaria (CSU) patients treated with omalizumab
A decline of FcεRI on basophils was observed within 1 week after initiation and during omalizumab treatment, as shown in earlier studies.[7,8]
Summary
Chronic spontaneous urticaria (CSU) manifests as a skin disease with a sudden onset of weals, which last longer than 6 weeks. Objective: In this study, we assessed the responsiveness and FcεRI expression of various subsets of leucocytes in patients with CSU treated with omalizumab. Results: In addition to a rapid and significant reduction in FcεRI on basophils, we demonstrated a reduction in FcεRI on plasmacytoid dendritic cells during omalizumab treatment, which persisted until 3 months after discontinuation. Apart from clinical non-responders showing a stronger increase in anti-IgE–induced basophil degranulation over a period time, no differences were found in omalizumab responders vs non-responders. Conclusions/Clinical Relevance: FcεRI expression on basophils decreased rapidly, while anti-IgE–induced degranulation significantly increased due to omalizumab treatment in patients with CSU, persisting at least for 3 months after stopping the treatment. Whether basophils play a role in omalizumab responsiveness in CSU remains unclear
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.